News | December 20, 2022
Ipca acquires further 6.53% of equity share of Trophic Wellness
Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.
Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Positive opinions based on significant survival benefit
The product is backed by required scientific proof and comparative bioequivalence studies
Post the sale, Patel family has become the single largest promoter shareholder in the company
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
UHI is envisioned as a foundational layer of the Ayushman Bharat Digital Mission and aims to enable interoperability in health services in India through open protocols
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Subscribe To Our Newsletter & Stay Updated
